Abstract:Glycosylation is the most complex post-translational modification of proteins. Altered glycans on the tumor- and host-cell surface and in the tumor microenvironment have been identified to mediate critical events in cancer pathogenesis and progression. Tumor-associated glycan changes comprise increased branching of N-glycans, higher density of O-glycans, generation of truncated versions of normal counterparts, and generation of unusual forms of terminal structures arising from sialylation and fucosylation. The functional role of tumor-associated glycans (Tn, sTn, T, and sLea/x) is dependent on the interaction with lectins. Lectins are expressed on the surface of immune cells and endothelial cells or exist as extracellular matrix proteins and soluble adhesion molecules. Expression of tumor-associated glycans is involved in the dysregulation of glycogenes, which mainly comprise glycosyltransferases and glycosidases. Furthermore, genetic and epigenetic mechanisms on many glycogenes are associated with malignant transformation. With better understanding of all aspects of cancer-cell glycomics, many tumor-associated glycans have been utilized for diagnostic, prognostic, and therapeutic purposes. Glycan-based therapeutics has been applied to cancers from breast, lung, gastrointestinal system, melanomas, and lymphomas but rarely to neuroblastomas (NBs). The success of anti-disialoganglioside (GD2, a glycolipid antigen) antibodies sheds light on glycan-based therapies for NB and also suggests the possibility of protein glycosylation-based therapies for NB. This review summarizes our understanding of cancer glycobiology with a focus of how protein glycosylation and associated glycosyltransferases affect cellular behaviors and treatment outcome of various cancers, especially NB. Finally, we highlight potential applications of glycosylation in drug and cancer vaccine development for NB.

Sialic Acid—Modified Nanoparticles—New Approaches in the Glioma Management—Perspective Review

Tumor Microenvironment Targeting System for Glioma Treatment Via Fusion Cell Membrane Coating Nanotechnology.

Engineered Cell Membrane-Coated Nanoparticles: New Strategies in Glioma Targeted Therapy and Immune Modulation

Exploration of sialic acid receptors as a potential target for cancer treatment: A comprehensive review

Liposomal Nanomaterials: A Rising Star in Glioma Treatment

Sialic acid metabolism orchestrates transcellular connectivity and signaling in glioblastoma

Targeted Nanotechnology in Glioblastoma Multiforme

Glioma nanomedicine: Design, fabrication and theranostic application

Targeted Polymeric Nanoparticles as a Strategy for the Treatment of Glioblastoma: A Review

Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates

Application of Cell Membrane-Functionalized Biomimetic Nanoparticles in the Treatment of Glioma

Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity

Recent Advancements in Liposome-Targeting Strategies for the Treatment of Gliomas: A Systematic Review

Analyzing and Modifying Sialic Acid at the Glycan End: Systematic Review of Methods and Functional Outcomes

Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies

Progress of nanoparticle drug delivery system for the treatment of glioma

How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature

Contemporary strategies in glioblastoma therapy: Recent developments and innovations

Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma

Sialylation: an Avenue to Target Cancer Cells

Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions